Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.
Making clinical decisions for patients with intermediate-risk acute myeloid leukemia (AML) based on their measurable residual disease (MRD) following remission may help facilitate better treatment optimization, according to a new study.
Based on subgroup analyses of over 500 younger patients (14-60 years) with intermediate-risk disease, the researchers say MRD-guided decisions may be associated with better treatment stratification and improved postremission treatment. They note that prospective multicenter trials are needed to validate these findings.
According to the researchers, while MRD has been widely adopted as a stratification tool for treatment, the association of dynamic MRD with treatment following remission in these patients is not well understood.
“It remains a challenge for practitioners to choose the optimal [postremission treatment] for patients with IR-AML because different conclusions have been drawn in previous reports,” explained the researchers, explaining that while some research has indicated that patients with intermediate-risk AML may fare better with allo-SCT, other research has indicated that chemotherapy or auto-SCT may yield better survival.
The study had a few important findings, including:
Based on the findings, the researchers suggest: “[Chemotherapy] and auto-SCT might be preferable for the persistent MRD-negative patients, and allo-SCT should be strongly recommended for the persistent MRD-positive and recurrent MRD-positive patients. Auto-SCT prior to allo-SCT might be recommended for the patients who were MRD negative after 2 cycles of chemotherapy. Allo-SCT might be preferable for the patients who were MRD negative after 3 cycles of chemotherapy.”
Throughout the study period, 146 of the patients relapsed, with a median time from the first course of chemotherapy to relapse of 10.9 months. Patients receiving allo-SCT had the longest time to relapse with a median time to relapse of 13 months compared with a median 10.9 months among patients receiving auto-SCT and a median 9.9 months among patients receiving chemotherapy.
Reference
Yu S, Fan Z, Ma L, et al. Association between measurable disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes. JAMA Netw Open. 2021;4(7):e2115991.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More